Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 3

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
  
    Treasury
     Stock  
    Shareholders’
    Equity  
    controlling
     Interest  
    Total
    Equity 

    Balance,
    April 30, 2025 
     32,211,092  
    $322  
    $262,470  
    $(246,724) 
    $-  
    $16,068  
    $(1,162) 
    $14,906
  
    Stock
    option compensation to employees and directors 
     -  
     -  
     829  
     -  
     -  
     829  
     -  
     829 
  
    Stock
    options issued to consultants 
     -  
     -  
     26  
     -  
     -  
     26  
     -  
     26 
  
    Offering
    expenses related to an at-the-market offering 

    Common
    stock issued in an at-the-market offering, net of offering expenses of $73 
     596,974  
     6  
     1,922  
     -  
     -  
     1,928  
     -  
     1,928 
  
    Common
    stock issued upon exercise of stock options 
     14,043  
     -  
     2  
     -  
     -  
     2  
     -  
     2 
  
    Common
    stock issued to consultants 

    Common
    stock issued to consultants, shares 

    Common
    stock issued pursuant to an employee stock purchase plan 

    Common
    stock issued pursuant to an employee stock purchase plan, shares 

    Cancelation of treasury
    shares 

    Cancelation of treasury
    shares, shares 

    Net
    loss 
     -  
     -  
     -  
     (2,258) 
     -  
     (2,258) 
     (22) 
     (2,280)
  
    Balance,
    July 31, 2025 
     32,822,109  
    $328  
    $265,249  
    $(248,982) 
    $-